vs

Side-by-side financial comparison of Avidia Bancorp, Inc. (AVBC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $26.8M, roughly 1.3× Avidia Bancorp, Inc.). Avidia Bancorp, Inc. runs the higher net margin — 22.9% vs -304.2%, a 327.2% gap on every dollar of revenue. Avidia Bancorp, Inc. produced more free cash flow last quarter ($24.1M vs $-47.3M).

Avidia Bank is an American mutual community bank headquartered in Hudson, Massachusetts. It was founded in 2007 when it was formed by a merger between Hudson Savings Bank and Westborough Bank.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

AVBC vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.3× larger
RXRX
$35.5M
$26.8M
AVBC
Higher net margin
AVBC
AVBC
327.2% more per $
AVBC
22.9%
-304.2%
RXRX
More free cash flow
AVBC
AVBC
$71.4M more FCF
AVBC
$24.1M
$-47.3M
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVBC
AVBC
RXRX
RXRX
Revenue
$26.8M
$35.5M
Net Profit
$5.3M
$-108.1M
Gross Margin
59.8%
Operating Margin
33.3%
-304.8%
Net Margin
22.9%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVBC
AVBC
RXRX
RXRX
Q4 25
$26.8M
$35.5M
Q3 25
$28.0M
$5.2M
Q2 25
$25.9M
$19.2M
Q1 25
$22.9M
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
AVBC
AVBC
RXRX
RXRX
Q4 25
$5.3M
$-108.1M
Q3 25
$-907.0K
$-162.3M
Q2 25
$3.9M
$-171.9M
Q1 25
$-11.6M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
AVBC
AVBC
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
AVBC
AVBC
RXRX
RXRX
Q4 25
33.3%
-304.8%
Q3 25
-7.0%
-3327.6%
Q2 25
19.4%
-916.8%
Q1 25
-72.0%
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
AVBC
AVBC
RXRX
RXRX
Q4 25
22.9%
-304.2%
Q3 25
-3.2%
-3135.3%
Q2 25
15.0%
-894.2%
Q1 25
-50.5%
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
AVBC
AVBC
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.05
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVBC
AVBC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$275.0M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$379.0M
$1.1B
Total Assets
$2.8B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVBC
AVBC
RXRX
RXRX
Q4 25
$275.0M
$743.3M
Q3 25
$208.3M
$659.8M
Q2 25
$592.5M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
AVBC
AVBC
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
AVBC
AVBC
RXRX
RXRX
Q4 25
$379.0M
$1.1B
Q3 25
$372.0M
$1.0B
Q2 25
$191.4M
$919.1M
Q1 25
$186.1M
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
AVBC
AVBC
RXRX
RXRX
Q4 25
$2.8B
$1.5B
Q3 25
$2.8B
$1.4B
Q2 25
$3.0B
$1.3B
Q1 25
$2.7B
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
AVBC
AVBC
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVBC
AVBC
RXRX
RXRX
Operating Cash FlowLast quarter
$28.4M
$-46.1M
Free Cash FlowOCF − Capex
$24.1M
$-47.3M
FCF MarginFCF / Revenue
89.9%
-133.1%
Capex IntensityCapex / Revenue
16.0%
3.5%
Cash ConversionOCF / Net Profit
5.32×
TTM Free Cash FlowTrailing 4 quarters
$40.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVBC
AVBC
RXRX
RXRX
Q4 25
$28.4M
$-46.1M
Q3 25
$24.1M
$-117.4M
Q2 25
$-2.3M
$-76.4M
Q1 25
$-2.2M
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
AVBC
AVBC
RXRX
RXRX
Q4 25
$24.1M
$-47.3M
Q3 25
$23.3M
$-117.6M
Q2 25
$-3.3M
$-79.6M
Q1 25
$-3.9M
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
AVBC
AVBC
RXRX
RXRX
Q4 25
89.9%
-133.1%
Q3 25
83.2%
-2272.5%
Q2 25
-12.8%
-413.9%
Q1 25
-16.9%
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
AVBC
AVBC
RXRX
RXRX
Q4 25
16.0%
3.5%
Q3 25
3.1%
4.7%
Q2 25
3.7%
16.4%
Q1 25
7.2%
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
AVBC
AVBC
RXRX
RXRX
Q4 25
5.32×
Q3 25
Q2 25
-0.60×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons